19 results about "Prednisone" patented technology

The invention relates to the technical field of nursing in the rheumatism and immunology department, in particular to an intelligent patient personalized nursing path management system in the rheumatism and immunology department, which comprises a joint activity-inflammation data acquisition unit, a path generation and dose binding unit, a cross-modal verification feedback unit and a closed-loop priority regulation and control unit, multi-modal data such as joint angles and inflammatory factors are collected through detection and fusion of a nine-axis inertial sensor and a biomarker, the morning stiffness period is recognized through a time sequence segmentation model, the dosage of prednisone is dynamically adjusted in combination with a hormone dosage response rule base, and the effectiveness of rehabilitation actions is verified based on a dynamic time warping algorithm. When the medicine taking time deviation exceeds one hour or the action execution is abnormal, a sensor is triggered to enhance the acquisition and dose increment mechanism, and meanwhile, the priority of a nursing instruction is optimized through a conflict arbitration mechanism, so that the full-process intelligence of data acquisition, path generation, verification feedback and priority regulation is realized, and an accurate nursing scheme is provided for patients in the rheumatism immunology department.

The invention belongs to the technical field of tumor resistance, and particularly relates to a cabazitaxel albumin composition and application thereof. The cabazitaxel albumin composition comprises cabazitaxel and human serum albumin, and does not contain a surfactant; the solution is a clear solution in a liquid state; the present invention relates to a Cabazitaxel injection for use in the treatment of a cancer patient by infusion administration, the dosage of Cabazitaxel infused to said patient being about 10-40 mg / m2, preferably 20 mg / m2 or 25 mg / m2, optionally in combination with a corticoid, such as prednisone, optionally repeatedly administered to said patient at a new cycle per 3 weeks, having lower adverse effects than originally developed Cabazitaxel injections, and more particularly to a Cabazitaxel injection for use in the treatment of cancer patients. And a higher disease control rate is achieved for patients with advanced solid tumors.

Provided are methods and compositions, for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib; a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.

The present disclosure relates to the use of cortisol, cortisone, cortisone acetate, hydrocortisone, fludrocortisone, prednisolone, prednisone, methylprednisolone, Dehydroepiandrosterone (DHEA), dexamethasone, betamethasone, adrenocorticotropic hormone (ACTH), ganaxolone, tetracosactide or combinations thereof for preventing and / or reducing the risk of Sudden Unexpected Death in Epilepsy (SUDEP). The disclosure further provides pharmaceutical compositions and methods for preventing and / or reducing the risk of SUDEP, particularly in Dravet Syndrome patients.

The present invention discloses a method for constructing a fetal osteoarthritis model caused by prednisone exposure during pregnancy, an intervention target, and its application. circGtdc1 is a newly identified circRNA that is most significantly altered in dysplastic cartilage caused by prednisone exposure during pregnancy. RNase R, AcD, and Sanger sequencing confirmed its circularization. Prednisolone concentration-dependently reduced circGtdc1 expression in chondrocytes. Silencing circGtdc1 significantly inhibited chondrocyte proliferation and matrix synthesis gene expression, while overexpression of circGtdc1 had the opposite effect and could reverse the effects of prednisolone. Intra-articular injection of AAV‑circGtdc1 to overexpress circGtdc1 can reverse chondrodysplasia caused by prednisone exposure during pregnancy. The intervention target established by the present invention is novel, reliable, and simple, providing a possibility for the early prevention and treatment of fetal osteoarthritis.

The present disclosure relates to niraparib and abiraterone acetate, plus prednisone or prednisolone; for use in a method of improving the efficacy of treatment of metastatic castration-resistant prostate cancer (mCRPC) in a patient with DNA-repair anomalies, in particular for improving the median radiographic progression-free survival (rPFS).

This invention provides a strain of *Lactobacillus plantarum*, and discloses the fermentation product of *Eucommia ulmoides* leaves, *Rehmannia glutinosa*, dried ginger, and *Dendrobium officinale* obtained by fermenting these herbs, along with its preparation method and applications. This fermentation product can directionally activate the phenylpropane biosynthetic pathway, inducing the generation of characteristic small molecule metabolites of polyphenols, particularly sanguranyl sulfadiazine (SSA). Moreover, compared to the raw materials, the fermentation product contains more active small molecule metabolites. Finally, experiments on zebrafish modeled with prednisone demonstrated that the fermentation product can significantly promote bone formation. The fermentation product mainly restores the expression levels of related genes to normal zebrafish gene expression levels by regulating these genes. Therefore, the fermentation product can be used to prepare foods or medicines that improve bone health.

The invention discloses a self-assembly double-enzyme compound, a preparation method and application of the self-assembly double-enzyme compound in synthesis of a prednisone intermediate, and the self-assembly double-enzyme compound is obtained by fusing 11 alpha-hydroxylase and 1, 2-dehydrogenase on the basis of a SpyCatcher / SpyTag system. According to the method, a self-assembled double-enzyme compound of 11alpha-hydroxylase and 1, 2-dehydrogenase is constructed through a SpyCatcher / SpyTag system, 17alpha-hydroxyprogesterone is taken as a substrate, double-enzyme cascade one-step catalytic reaction is realized, the reaction process is simplified, and separation and purification operation of an intermediate product is omitted. The self-assembled double-enzyme compound constructed by the invention forms a high-efficiency substrate channel, accelerates the rapid transfer of an intermediate from a catalytic activity center of a first enzyme to a catalytic activity center of a second enzyme, improves the catalytic efficiency, is suitable for industrial application, and has a conversion rate of 99.6%.

The present invention belongs to the technical field of anti-tumor medicine. Provided are a cabazitaxel albumin composition and the use thereof. The cabazitaxel albumin composition comprises cabazitaxel and a human serum albumin, and does not contain a surfactant. The cabazitaxel albumin composition is a clear solution in a liquid state, which is administered by means of infusion for the treatment of a cancer patient. The dosage of the cabazitaxel infused to the patient is about 10-40 mg / m 2, preferably 20 mg / m 2 or 25 mg / m 2. The cabazitaxel albumin composition is optionally used in combination with a corticosteroid (such as prednisone), and is optionally administered repeatedly to the patient every 3 weeks as a new cycle. The cabazitaxel albumin composition has fewer adverse effects and a higher disease control rate for a patient with advanced solid tumors compared to the originally developed cabazitaxel injection.

The invention provides a plant lactobacillus, and also discloses a secondary yellow fermented product obtained by fermenting eucommia ulmoides leaves, rehmannia, dried ginger and dendrobium officinale with the plant lactobacillus as well as a preparation method and application of the secondary yellow fermented product. The sec-yellow leavening can directionally activate a phenylpropane biosynthetic pathway and induce the generation of polyphenol characteristic small molecule metabolites, especially the generation of mulberry furan W. The invention also discloses a preparation method of the sec-yellow leavening. And compared with the raw materials, the fermented product has more active small molecule metabolites. Finally, zebra fish experiments after prednisone modeling prove that the sec-yellow yeast can significantly promote osteogenesis. The sec-yellow leavening is recovered to the normal zebrafish gene expression level mainly by regulating the related gene expression level. Therefore, the sec-yellow leavening can be applied to preparation of foods or medicines for improving bone health.

Methods and compositions are provided for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib, a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.

The present application relates to the technical field of rheumatology and immunology nursing, in particular to an intelligent rheumatology and immunology patient personalized nursing path management system, which comprises a joint activity-inflammation data acquisition unit, a path generation and dose binding unit, a cross-modal verification feedback unit and a closed-loop priority regulation unit. The present application fuses and acquires multi-modal data such as joint angle and inflammatory factors through a nine-axis inertial sensor and biomarker detection, identifies the morning stiffness period through a time series segmentation model, dynamically adjusts the prednisone dose in combination with a hormone dose response rule base, and verifies the effectiveness of rehabilitation movements based on a dynamic time warping algorithm. When the medicine taking time deviation is more than 1 hour or the movement execution is abnormal, the sensor enhanced collection and dose increment mechanism is triggered, and at the same time, the nursing instruction priority is optimized through a conflict arbitration mechanism, realizing the whole process intelligentization of "data acquisition-path generation-verification feedback-priority regulation" and providing precise nursing solutions for rheumatology and immunology patients.

The invention discloses a construction method and application of a rodent model for male adult offspring fertility reduction caused by prednisone exposure during pregnancy. The fertility of male adult offspring is reduced due to prednisone exposure during pregnancy, rodents are subjected to gavage with prednisone in the whole pregnancy process, and the offspring is normally fed for 12 weeks after being born. Male offspring testis or sperms which are 20 days after pregnancy and 12 weeks after birth are obtained, and fetal testis dysplasia and adult fertility reduction are proved. Based on the animal model, it is proved that male adult offspring fertility reduction caused by prednisone exposure during pregnancy can be reversed when genistein is given to pregnant rats at the same time during pregnancy. The animal model established by the invention has the characteristics of novelty, reliability, simplicity and convenience, and is of great significance to elucidating a fertility reduction mechanism of male offspring caused by prednisone exposure during pregnancy and exploring an early prevention and treatment technology of the male offspring.

The invention discloses a method for simultaneously improving the sensitivity and cross contamination resistance of a latex turbidimetric kit and application, and belongs to the technical field of biology. According to the method for simultaneously improving the sensitivity and the cross contamination resistance of the latex turbidimetric kit, latex microspheres used in a sensitization latex solution are low-mass-density latex microspheres, and the sensitization latex solution contains prednisone. According to the method disclosed by the invention, the sensitivity is improved by 39%-46%; meanwhile, after the reagent is subjected to cross contamination, the onboard service time is prolonged by 3-10 times, the scrapping time is prolonged from 2-3 days to 7-30 days for stabilization, and the basic use requirement is met.

The invention relates to a compound of formula:which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.

(3R, 4S)-3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H- chromen-7-ol (TRX-E-002-1) for use in a method of treatment for a hematological cancer being acute myeloid leukemia or multiple myeloma in a subject in need thereof, the method comprising administering to the subject an effective amount of TRX-E-002-1. The method may further comprise administering to the subject an effective amount of a second compound selected from the group consisting of (i) a BCL-2 inhibitor such as venetoclax, navitoclax or obatoclax, (ii) a deoxycytidine analogue chemotherapeutic such as cytarabine or gemcitabine, (iii) a hypomethylating agent such as azacitidine or decitabine, (iv) an anthracycline chemotherapeutic such as daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin or mitoxantrone, (v) a proteasome inhibitor such as carfilzomib, bortezomib, and ixazomib, (vi) an immunomodulatory drug such as pomalidomide, lenalidomide, and thalidomide and(vii) a corticosteroid drug such as dexamethasone or prednisone, and (viii) an alkylator such as bendamustine, cyclophosphamide, melphalan, and melflufen. Corresponding combination pharmaceutical compositions.

Described herein are methods for reducing an antibody response to uricase therapy, improving the treatment of gout, reducing uric acid levels, and preventing and / or delaying infusion reactions. The methods may include administration of a uricase and a steroid as described herein.

The use of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone in the preparation of a drug for treating peripheral T-cell lymphoma (PTCL). The PTCL is preferably treatment-naïve PTCL. Other first-line and second-line drugs for treating PTCL may also be further used on the basis of the foregoing. A method for treating PTCL, the method comprising administering, to a patient, a therapeutically effective amount of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone. The combined administration of the drugs is safe and tolerable, has a small toxicity and few side effects, and can obtain a higher total objective remission rate (ORR) in treatment-naïve PTCL patients.

The invention discloses a phenylbutazone peak shifting sustained release injection. Every 100 g of the phenylbutazone peak shifting sustained release injection is prepared from the following components by weight: 4.0 to 10.0 g of phenylbutazone, 3.0 to 9.0 g of polyethylene glycol 12000, 5.0 to 13.0 g of povidone C15, 8.0 to 18.0 g of ethyl oleate, 4.0 to 8.0 g of span 20, 1.0 to 3.0 g of behenic acid, 0.5 to 2.5 g of propylene glycol alginate, 0.1 to 2.0 g of propyl gallate and the balance of corn oil. The injection contains three kinds of phenylbutazone drug forms, the drug is released in different time periods after intramuscular injection, and the peak value of plasma concentration is staggered, so that the effect of staggered-peak release is realized. According to the technology, on one hand, the highest plasma concentration is reduced, the liver and kidney metabolism burden is remarkably relieved, and the safety is improved, on the other hand, the effective plasma concentration maintaining time is prolonged, the administration frequency is reduced, the stress reaction generated in the animal fixing process is reduced, and time and labor are saved. Meanwhile, the invention further discloses a preparation method, the process is easy to convert, and the application prospect is wide.